A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Acute Myocardial InfarctionModerate Renal Impairment
Interventions
BIOLOGICAL

CSL_112

CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.

OTHER

Placebo

0.9% weight/volume sodium chloride solution (ie, normal saline)

Trial Locations (31)

1122

Study Site 18001, Budapest

1134

Study Site 18005, Budapest

4400

Study Site 18007, Nyíregyháza

6720

Study Site 18009, Szeged

7624

Study Site 18003, Pécs

10249

Study Site 17005, Berlin

10967

Study Site 17009, Berlin

13100

Study Site 19008, Safed

13353

Study Site 17003, Berlin

20246

Study Site 17006, Hamburg

22100

Study Site 19002, Nahariya

27705

Study Site 16056, Durham

27762

Study Site 16014, High Point

32209

Study Site 16003, Jacksonville

35211

Study Site 16101, Birmingham

35801

Study Site 16078, Huntsville

49770

Study Site 16061, Petoskey

57701

Study Site 16018, Rapid City

65929

Study Site 17014, Frankfurt am Main

71301

Study Site 16208, Alexandria

76301

Study Site 16241, Wichita Falls

79106

Study Site 17001, Freiburg im Breisgau

80120

Study Site 16130, Littleton

83712

Study Site 16112, Boise

94520

Study Site 16168, Concord

3109601

Study Site 19005, Haifa

06810

Study Site 16135, Danbury

1815 JD

Study Site 21001, Alkmaar

1091 AC

Study Site 21006, Amsterdam

3818 TZ

Study Site 21017, Amsterfoort

6525 EC

Study Site 21008, Nijmegen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY